Previous 10 |
– Company is well positioned to achieve multiple corporate, clini...
Cocrystal Pharma (NASDAQ: COCP ): FY GAAP EPS of -$1.75. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement of important new treatments for influenza – – Clinic...
I have been studying what effect uplisting has on the stock price of individual stocks. My first article concluded that a profit exceeding 25% was available in 65% of stocks that had uplisted during 2015 but that profit evaporated within the first year after uplisting. Only 10% of these same...
BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today ...
Gainers: Boxlight Corporation (NASDAQ: BOXL ) +47% . Microbot Medical (NASDAQ: MBOT ) +33% . Regional Health Properties (NYSEMKT: RHE ) +33% . Blink Charging (NASDAQ: BLNK ) +27% . iFresh (NASDAQ: IFMK ) +18% . Planet Green Holdings (NYSEMKT: PLAG ) +15% . Daxor Corporation (NY...
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination therapy to include approved HCV DAAs (direct antiviral agents) - Company rep...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...